
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Meis1 CRISPR Activation Plasmid (h) | sc-401481-ACT | 20 µg | $397.00 | |||
Meis1 CRISPR Activation Plasmid (h2) | sc-401481-ACT-2 | 20 µg | $397.00 |
MEIS1 encodes a TALE homeobox transcription factor that forms cooperative complexes with HOX and PBX proteins to control lineage specification, hematopoietic stem and progenitor cell maintenance, and developmental patterning. Meis1 modulates transcriptional programs linked to cell-cycle control, differentiation, and chromatin regulation, including pathways coordinating self-renewal and maturation in blood and neural lineages. Dysregulated MEIS1 expression is frequently studied in the context of leukemogenesis and aberrant progenitor states, and genetic association studies implicate MEIS1-regulated networks in neurobiology and sleep-related traits. These features make MEIS1 a useful node for interrogating transcriptional circuitry, enhancer logic, and fate decisions in human cell models.
Meis1 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous MEIS1 expression without altering the underlying DNA sequence.
Meis1 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the MEIS1 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the MEIS1 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Meis1 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native MEIS1 locus and enabling the study of Meis1-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Meis1 pathway restoration in tumor cells with silenced or reduced MEIS1 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.